Barrington Research Upgrades Lifecore Biomedical to Outperform, Announces $5.5 Price Target

Barrington Research has upgraded Lifecore Biomedical (NASDAQ: LFCR) from Market Perform to Outperform, setting a price target of $5.5 for the stock. Analyst Michael Petusky made this announcement, indicating a positive outlook for the company's performance.